Medicamen Biotech Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medicamen Biotech Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $5.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medicamen Biotech Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $5.3M Trade | TransData Nexus

Medicamen Biotech Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $5.3M Total Trade · DGFT Verified

Medicamen Biotech Limited is an Indian pharmaceutical exporter with a total trade value of $5.3M across 8 products in 6 therapeutic categories. Based on 214 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Folic ($2.0M), Trimethoprim ($1.2M), Nystatin ($694.6K).

Medicamen Biotech Limited — Export Portfolio & Destination Treemap

Medicamen Biotech Limited pharmaceutical export portfolio — 8 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medicamen Biotech Limited? — Company Overview & Market Position

Medicamen Biotech Limited (MBL) is a pharmaceutical company established in December 1993, headquartered in New Delhi, India. The company is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 531146 and on the National Stock Exchange of India (NSE) under the ticker symbol MEDICAMEQ. As of March 12, 2026, MBL's market capitalization was approximately ₹3.54 billion (around $51.65 million USD). The company reported a revenue of ₹1.72 billion (approximately $18.55 million USD) for the trailing twelve months ending December 31, 2025. The Corporate Identification Number (CIN) assigned to MBL is L74899DL1993PLC056594. The company employs approximately 376 individuals. MBL's official website is www.medicamen.com.

What Does Medicamen Biotech Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Folic$2.0M 2Trimethoprim$1.2M

Product Portfolio — Top 8 by Export Value

Medicamen Biotech Limited exports 8 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Folic	Nutritional Supplements	$2.0M	41	3.7%	5
2	Trimethoprim	Advanced Antibiotics	$1.2M	49	4.4%	3
3	Nystatin	Antifungals	$694.6K	41	1.3%	14
4	Diphenhydramine	Antihistamines & Allergy	$519.8K	44	1.6%	12
5	Sulfamethoxazole	Advanced Antibiotics	$442.8K	18	2.2%	10
6	Norfloxacin	Advanced Antibiotics	$300.0K	6	3.6%	4
7	Glibenclamide	Advanced Diabetes Medications	$110.9K	11	0.3%	8
8	Mefloquine	Antimalarial & Antiparasitic	$28.3K	4	1.2%	7

Medicamen Biotech Limited exports 8 pharmaceutical products across 6 therapeutic categories with a total export value of $5.3M. The top category is Nutritional Supplements (38.7% of portfolio), followed by Advanced Antibiotics (35.8%), indicating a concentrated portfolio with the top 5 products accounting for 91.7% of total export value.

Medicamen Biotech Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

MBL operates two primary manufacturing facilities in India:

Bhiwadi Formulation Plant (Rajasthan): This facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. It has received WHO-GMP certification, indicating compliance with international manufacturing standards.

Haridwar Oncology Plant (Uttarakhand): Dedicated to the production of oncology injectables and oral solid dosages (OSDs), this plant has undergone a comprehensive audit by the US Food and Drug Administration (USFDA) in April 2023, positioning it for potential approvals in regulated markets.

These facilities underscore MBL's commitment to quality manufacturing and regulatory compliance.

3Key Leadership

The leadership team at Medicamen Biotech Limited includes:

Rajesh Madan: Chief Executive Officer (CEO)

Chandan Kumar: Chief Financial Officer (CFO)

Aneek Gupta: Chief Operating Officer (COO)

Parul Choudhary: Compliance Officer and Company Secretary

Ashwani Kumar Sharma: Whole-Time Director

These executives play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medicamen Biotech Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medicamen Biotech Limited has made significant strides in entering regulated markets:

United States: In July 2023, MBL filed its first Abbreviated New Drug Application (ANDA) for Bortezomib injections with the USFDA, marking a major milestone for the company.

European Union: In November 2024, the company's Bhiwadi manufacturing facility received EU GMP certification from the National Organisation for Medicines in Athens, Greece, facilitating access to European markets.

United Kingdom: The Bhiwadi facility's EU GMP certification also aligns with UK regulatory standards, enhancing market access.

Australia: While specific approvals are not detailed, the EU GMP certification positions MBL favorably for potential market entry.

Japan: No specific regulatory filings or approvals are reported; however, the company's global certifications may support future market access.

Medicamen Biotech Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Medicamen Biotech Limited's FDA status includes:

Facility Registrations: The Haridwar Oncology Plant underwent a comprehensive audit by the USFDA in April 2023, positioning it for potential approvals in regulated markets.

Approved ANDAs: In July 2023, MBL filed its first ANDA for Bortezomib injections with the USFDA, marking a significant milestone.

DMF Filings: The company has filed Drug Master Files (DMFs) with the USFDA for its Active Pharmaceutical Ingredients (APIs), demonstrating compliance with FDA standards.

Inspection History: The Haridwar facility's successful audit in April 2023 indicates a positive inspection history, enhancing the company's credibility.

These factors collectively strengthen MBL's position in the US market.

2WHO & EU GMP

Medicamen Biotech Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical industry, Medicamen Biotech Limited faces competition from both domestic and international companies. While specific competitors are not detailed, MBL's focus on quality manufacturing and regulatory compliance positions it favorably in the market. The company's certifications and approvals enhance its competitiveness, enabling it to meet the demands of regulated markets.

2Key Differentiators

Medicamen Biotech Limited's key differentiators include:

Quality Manufacturing: The company operates state-of-the-art facilities with WHO-GMP and EU GMP certifications, ensuring high-quality products.

Regulatory Compliance: MBL's successful audits and approvals from agencies like the USFDA

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — Medicamen Biotech Limited

How many pharmaceutical products does Medicamen Biotech Limited export from India?

Medicamen Biotech Limited exports 8 pharmaceutical products across 6 therapeutic categories. The top exports are Folic ($2.0M), Trimethoprim ($1.2M), Nystatin ($694.6K), Diphenhydramine ($519.8K), Sulfamethoxazole ($442.8K). Total export value is $5.3M.

What is Medicamen Biotech Limited's total pharmaceutical export value?

Medicamen Biotech Limited's total pharmaceutical export value is $5.3M, based on 214 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Medicamen Biotech Limited cover?

Medicamen Biotech Limited exports across 6 therapeutic categories. The largest are Nutritional Supplements (38.7%, 1 products), Advanced Antibiotics (35.8%, 3 products), Antifungals (13.1%, 1 products).

Get Full Medicamen Biotech Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.